April 26, 2016
In this webinar, Dr. Marc-Andre Dansereau from the Université de Sherbrooke will describe how RNAi was used to better understand how the CCL2 chemokine and its receptor, CCR2, contribute to the development of chronic pain. Although CCR2 has been identified as an interesting target for the development of a new class of analgesic drug, its regulation in the context of chronic pain is still widely unknown. Injecting Dicer-substrate siRNA against CCL2 or CCR2 encapsulated in lipid nanoparticles (LNP) into the intrathecal space after the induction of chronic inflammatory pain in rats revealed a biphasic contribution of this chemokine system, as well as a differential role of dorsal root ganglia-derived CCL2 and CCR2.